

## Press Release

For further information:

Peter Friedli  
Freigutstrasse 5  
8002 Zürich  
Tel: 044/283 29 00  
Email: peter.friedli@friedlicorp.ch

### Lock-up and loan agreements

Zürich, July 20, 2005. New Venturetec (SWX: NEV) announced today material agreements.

New Venturetec entered into a 5 year lock-up agreement with Osiris Therapeutics, Inc., Baltimore, USA. The Company agreed that it will not, without the express written consent of Osiris Therapeutics, Inc. and Friedli Corporate Finance, Inc., offer, sell or contract to sell, trade, transfer or otherwise dispose of, directly or indirectly (including short sales and other hedging or derivative transactions) (collectively, transfer), any Osiris Therapeutics securities held by New Venturetec for a period of 5 years until June 30, 2010.

In addition the Board of Directors of New Venturetec and the lender of certain loans, including Peter Friedli agreed what follows:

If the general assembly decides at any time to change the board or vote against the proposal of the board in order to elect directors other than the current members or to terminate the investment management agreement with Friedli Corporate Finance, Inc., Belize, the loans will be immediately due and all loan transactions will be unwinded through the redemption with all the securities secured and purchased with. The accrued management fee will be due and be paid through cash or securities at the board's sole discretion.

New Venturetec is a publicly traded Swiss investment company (SWX: NEV) which invests directly in Venture Capital Companies predominately in the USA.

The Ordinary Shareholder Meeting 2005 takes place November 29, 2005 at the UBS Konferenzgebäude Grünenhof, Nüscherstrasse 9 in Zürich. The following companies will present: E-centives, Osiris Therapeutics and Basilea Pharmaceutica.